Literature DB >> 1563389

Use of ciprofloxacin in the treatment of brucellosis.

M Doğanay, B Aygen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1563389     DOI： 10.1007/bf01971279

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  2 in total

1.  Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.

Authors:  M Y Khan; M Dizon; F W Kiel
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.

Authors:  J Bosch; J Liñares; M J López de Goicoechea; J Ariza; M C Cisnal; R Martin
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790
  2 in total
  8 in total

Review 1.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 2.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

Review 3.  Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis.

Authors:  Julián Solís García del Pozo; Javier Solera
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

4.  Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647].

Authors:  Emine Alp; Rahmi Kemal Koc; Ahmet Candan Durak; Orhan Yildiz; Bilgehan Aygen; Bulent Sumerkan; Mehmet Doganay
Journal:  BMC Infect Dis       Date:  2006-04-11       Impact factor: 3.090

Review 5.  Bovine brucellosis - a comprehensive review.

Authors:  Sandip Kumar Khurana; Anju Sehrawat; Ruchi Tiwari; Minakshi Prasad; Baldev Gulati; Muhammad Zubair Shabbir; Rajesh Chhabra; Kumaragurubaran Karthik; Shailesh Kumar Patel; Mamta Pathak; Mohd Iqbal Yatoo; Vivek Kumar Gupta; Kuldeep Dhama; Ranjit Sah; Wanpen Chaicumpa
Journal:  Vet Q       Date:  2021-01-01       Impact factor: 3.320

6.  Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.

Authors:  Javier Ariza; Mile Bosilkovski; Antonio Cascio; Juan D Colmenero; Michael J Corbel; Matthew E Falagas; Ziad A Memish; Mohammad Reza Hasanjani Roushan; Ethan Rubinstein; Nikolaos V Sipsas; Javier Solera; Edward J Young; Georgios Pappas
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

7.  Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179].

Authors:  Oguz Karabay; Irfan Sencan; Derya Kayas; Idris Sahin
Journal:  BMC Infect Dis       Date:  2004-06-23       Impact factor: 3.090

8.  A randomized, comparative study of dual therapy (doxycycline-rifampin) versus triple therapy (doxycycline-rifampin-levofloxacin) for treating acute/subacute brucellosis.

Authors:  Ahmad Hasanain; Reem Mahdy; Asmaa Mohamed; Mostafa Ali
Journal:  Braz J Infect Dis       Date:  2016-04-14       Impact factor: 3.257
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.